IGES Life Science at the health economics conference ISPOR Europe 2023

Berlin, 07. November 2023 (IGES Institut) - The particular focus on the EU HTA procedure is primarily due to the existing time pressure: the first medicinal products have to undergo this EU-wide clinical evaluation procedure in less than 15 months. The procedure itself also takes place under great time pressure - with very tight deadlines and largely parallel to the approval process.

As stakeholders, the two IGES companies IGES Institut and Basel-based HealthEcon AG have contributed to the public consultations on the development of guidelines and guidance documents as part of the EUnetHTA21 activities. Participating experts will be present at ISPOR.

In the area of drug market analyses, IGES experts will present studies on the benefit assessment of orphan drugs in Germany. Among other things, they will show which factors influence the therapy costs of orphan drugs when they undergo a benefit assessment procedure again due to exceeding a sales threshold in Germany.

With its IGES LifeScience division, the IGES Group offers a wide range of research and consulting services for global developers and manufacturers of pharmaceuticals, medical devices and digital health applications. The services support all phases of the product life cycle management of new developments. They are geared towards the most important European healthcare markets.

ISPOR is the world's leading organization for health economics and outcomes research (HEOR). The congress, which takes place in Copenhagen from November 12 to 15, is one of the organization's largest annual events. The IGES Group has been contributing to the ISPOR program for many years.

IGES at ISPOR: HTA, Market Access and Strategy in Europe, EU-HTA Stakeholder.

Meet our Experts at
Booth C4-117
Floor Plan

12-15 November 2023

Bella Center
Center Blvd. 5, 2300
Copenhagen, Denmakr